Navigation Links
Landmark study describes prostate cancer metastasis switch
Date:4/2/2013

Prostate cancer doesn't kill in the prostate it's only once the disease travels to bone, lung, liver, etc. that it turns fatal. Previous studies have shown that loss of the protein E-Cadherin is essential for this metastasis. A University of Colorado Cancer Center study published this week in the Journal of Biological Chemistry describes for the first time a switch that regulates the production of E-Cadherin: the transcription factor SPDEF turns on and off production, leading to metastasis or stopping it cold in models of prostate cancer.

"When E-Cadherin is lost, cells become 'rouge' they can detach from their surrounding tissues, move effortlessly through the circulatory system, grow and attach at new sites. In prostate tumors that had lost E-Cadherin, we put in SPDEF and the tumors once again expressed E-Cadherin. They were once again anchored in place and unable to metastasize. We can make these 'rouge' cells back into epithelial-like cells and these epithelial cells stay anchored and lose the ability to migrate," says Hari Koul, PhD, investigator at the CU Cancer Center and professor and director of Urology Research at the University of Colorado School of Medicine, the study's senior author.

In fact, the work could have implications far beyond prostate cancer, as increasing evidence points to loss of E-Cadherin as a prerequisite for metastasis in many cancers.

Koul and colleagues first showed that E-Cadherin levels varied directly with the addition or subtraction of SPDEF. Then the group artificially knocked down E-Cadherin despite the presence of SPDEF and showed that cells remained able to migrate and invade new tissues (SPDEF didn't by itself affect metastasis and was instead dependent on modulating E-Cadherin, which is the driver). The group also showed a one-way switch SPDEF regulates E-Cadherin, but E-Cadherin expression does nothing to affect levels of SPDEF.

"Taken together, these studies paint a pretty compelling picture of SPDEF working in part through the modulation of E-Cadherin to inhibit prostate cancer metastasis," Koul says. "To the best of our knowledge these are the first studies demonstrating the requirement of SPDEF for expression of E-Cadherin."

Koul says that his group is getting very close to turning off the loss of E-Cadherin in cancer cells by re-arming tumors with the gene that makes SPDEF and my testing small molecules that increase SPDEF in cancer cells.

"This could be a real landmark," Koul says. "We see a prerequisite for metastasis and now we have a very clear picture of how to remove this necessary condition for the most dangerous behavior of prostate cancer."


'/>"/>

Contact: Garth Sundem
garth.sundem@ucdenver.edu
University of Colorado Denver
Source:Eurekalert

Related biology news :

1. NYBG press publishes final volume of landmark Intermountain Flora series
2. Study reveals risk factors for blood clots in pregnant and postnatal women
3. Southern California sagebrush better suited to climate change, UCI study finds
4. Study documents decimation of critically endangered forest elephant
5. Notre Dame researcher is studying role small dams play in pollution control
6. New study identifies unique mechanisms of antibiotic resistance
7. Appetite genes are key to better diets for poultry, study shows
8. Study finds strong genetic component to childhood obesity
9. Einstein study reveals new approach for stopping herpes infections
10. New lung cancer study takes page from Googles playbook
11. Study shows resources giveaway in Latin America; Outdated model tramples human rights, environment
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:5/20/2016)... -- VoiceIt is excited to announce its new marketing ... working together, VoiceIt and VoicePass will offer an ... slightly different approaches to voice biometrics, collaboration between ... Both companies ... "This marketing and technology partnership allows VoiceIt ...
(Date:5/3/2016)... VILNIUS, Lithuania , May 3, 2016 /PRNewswire/ ... today released the MegaMatcher Automated Biometric Identification ... deployment of large-scale multi-biometric projects. MegaMatcher ABIS can ... and accuracy using any combination of fingerprint, face ... of MegaMatcher SDK and MegaMatcher ...
(Date:4/26/2016)... April 27, 2016 Research ... Multi-modal Biometrics Market 2016-2020"  report to their offering.  ... The analysts forecast the global multimodal ... 15.49% during the period 2016-2020.  Multimodal ... sectors such as the healthcare, BFSI, transportation, automotive, ...
Breaking Biology News(10 mins):
(Date:6/23/2016)... ... 23, 2016 , ... Mosio, a leader in clinical research ... Recruitment and Retention Tips.” Partnering with experienced clinical research professionals, Mosio revisits the ... tools, and strategies for clinical researchers. , “The landscape of how patients receive ...
(Date:6/23/2016)... - FACIT has announced the creation of a ... Propellon Therapeutics Inc. ("Propellon" or "the Company"), to ... of first-in-class WDR5 inhibitors for the treatment of ... an exciting class of therapies, possessing the potential ... patients. Substantial advances have been achieved with the ...
(Date:6/23/2016)... (PRWEB) , ... June 23, 2016 , ... ... Plate® YM (Yeast and Mold) microbial test has received AOAC Research Institute approval ... of microbial tests introduced last year,” stated Bob Salter, Vice President of Regulatory ...
(Date:6/23/2016)... SAN FRANCISCO , June 23, 2016   ... it has secured $1 million in debt financing from ... to ramp up automation and to advance its drug ... for its new facility. "SVB has been ... goes beyond the services a traditional bank would provide," ...
Breaking Biology Technology: